Biotech RadarJobs updated

COMPANY

Kyverna Therapeutics

HQ: Emeryville, CA source · kyvernatx.com ↗ · West Coast

Clinical Phase 3

Kyverna runs clinical trials of therapies for B-cell-driven autoimmune diseases. From company website Source · Oct 12, 2026

Keywords: autoimmune Lupus Nephritis Lupus Nephritis - WHO Class IV Stiff-Person Syndrome Multiple Sclerosis Lupus Nephritis - WHO Class III Lupus Nephritis - World Health Organization (WHO) Class III Systemic Sclerosis Systemic Sclerosis - Diffuse Cutaneous Systemic Sclerosis - 2013 ACR/EULAR Classification Criteria Myasthenia Gravis Generalized Myasthenia Gravis Refractory Lupus Nephritis Myasthaenia Gravis Rheumatoid Arthritis Dermatomyositis Primary Progressive Multiple Sclerosis Secondary Progressive Multiple Sclerosis KYV-101

Location: Emeryville, CA · source · Oct 15, 2026

Profile checked Oct 10, 2026

$100.0MRaised (2 yrs)7Trials (company is sponsor)

Timeline

  1. Raise Follow-on offering: $100M (total, as published), announced Dec 17, 2025. Source: company release on GlobeNewswire. source ↗
  2. Trial start —: A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101 source ↗
  3. Debt Debt financing: $150M (up to, as announced), announced Nov 3, 2025. Source: SEC filing. source ↗
  4. Trial start Phase 2: KYSA-8: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Treatment Refractory Stiff Person Syndrome source ↗
  5. Trial start Phase 2: KYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis source ↗
  6. Trial start Phase 2/Phase 3: KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis source ↗
  7. Trial start Phase 1/Phase 2: KYSA-5: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Systemic Sclerosis source ↗
  8. Trial start Phase 1/Phase 2: KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis source ↗
  9. Trial start Phase 1/Phase 2: KYSA-3: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $100.0M · Debt: $150.0M. Last 2 years.

Clinical trials (lead sponsor) 7

RecordTitlePhaseStatusStartPrimary completion
NCT06342960KYSA-3: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus NephritisPhase 1/Phase 2TerminatedDec 1, 2022Dec 22, 2025 (actual)
NCT05938725KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus NephritisPhase 1/Phase 2TerminatedApr 28, 2023May 29, 2026 (actual)
NCT06400303KYSA-5: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Systemic SclerosisPhase 1/Phase 2TerminatedAug 6, 2024Jun 16, 2026 (actual)
NCT06193889KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia GravisPhase 2/Phase 3RecruitingAug 28, 20242027-09 (estimated)
NCT06588491KYSA-8: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Treatment Refractory Stiff Person SyndromePhase 2CompletedSep 25, 2024Jun 25, 2026 (actual)
NCT07403188A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101Not listedRecruitingNov 24, 20252041-01 (estimated)
NCT06384976KYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple SclerosisPhase 2Active, not recruitingSep 20, 20242027-04 (estimated)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

Feedback